This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
Bankruptcies, restructurings, clinical trial setbacks, and falling stock prices: It’s been a disconcerting week in Biotech Land. Luckily, this newsletter has arrived like a warm hug. I want to hear from you! Send me email at [email protected].
Weed for weight loss
Skye Bioscience was once a struggling, cash-starved penny stock. Today, the company is developing a treatment for obesity that was discovered through research into marijuana, and that might be additive to the GLP-1 blockbusters. Predictably, investors have taken notice.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect